Cancer drug trial halted early: what we know
NCT ID NCT02712905
First seen Nov 04, 2025 · Last updated Jun 18, 2026 · Updated 33 times
Summary
This study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find a safe dose and see if it could control the disease. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University
New York, New York, 10027, United States
-
Erasmus MC
Rotterdam, Netherlands
-
Institut Jules Bordet
Brussels, Belgium
-
Moores UCSD Cancer Center
La Jolla, California, 92093, United States
-
Netherland Cancer Institute
Amsterdam, Netherlands
-
Northwestern University
Chicago, Illinois, 60208, United States
-
Oregon Health Science University
Portland, Oregon, 97297, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
University of Alabama
Birmingham, Alabama, 35487, United States
-
University of Kansas Center for Research, Inc.
Kansas City, Kansas, 66045, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
VU Medical Center
Amsterdam, Netherlands
-
Vanderbilt University
Nashville, Tennessee, 37240, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.